Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
RADIATION: SIB-IMRT|DRUG: Paclitaxel|DRUG: Platinum-Based Drug|DRUG: Paclitaxel|DRUG: Platinum-Based Drug|OTHER: Involved Field Irradiation (IFI)
Overall survival (OS), 1 year|Overall survival (OS), 2 year|Overall survival (OS), 3 year
Progression-free survival (PFS), 1 year|Progression-free survival (PFS), 2 year|Progression-free survival (PFS), 3 year|Local recurrence-free rate（LRFS）, 1 year|Local recurrence-free rate（LRFS）, 2 year|Local recurrence-free rate（LRFS）, 3 year|Completion Rate, up to 2 year|Adverse events, up to 5 year
The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.